The resulting ROS released in the tumour microenvironment impaired the cytotoxic activity of NK cells by oxidising a serine residue in the initiation factor eIF2B, leading to downregulation of NKG2D and its ligands.167 These results provide evidence for an AKT/ROS-mediated mechanism to inhibit innate immune response in the tumour microenvironment. The gene discussed is AKT1; the disease is neoplasm.